To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Presented to Tertiary Care Hospital

ConditionChronic Plaque Psoriasis

Trial statusRecruiting

Trial phaseEarly Phase 1

Trial typeInterventional

Biological sexAll

Age18-60

SponsorSyeda Sana Zaman

About this trial

This study aims to compare efficacy of methotrexate vs apremilast in the management of chronic plaque psoriasis.Given the high prevalence of psoriasis in Pakistan and the significant psychological impact on patients, particularly in Peshawer,this study will provide valuable insights into optimal treatment strategies.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial design

Design model

Parallel

Treatments tested in this trial

Methotrexate
Drug
Group A will recieve methotrexate 10-25mg once weekly for 3 months. Along with folic acid once daily except on day of methotrexate.
Apremilast
Drug
Group B will recieve tablet apremilast 30mg twice daily for 3 months.

Treatment groups

106 Participants

are divided into 2 treatment groups

Group A: MethotrexateExperimental treatment 1 intervention

Group B: ApremilastExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

PASI SCORE calculation

Efficacy of drugs are measured by calculation of PASI score for both groups at each visit.A treatment will be deemed effective if it achieves 75% reduction in PASI score from the baseline in 12 weeks. Score ranges from 0 (no disease) to 72( maximums severity) Interpretation: 0-5 mild 6-10 moderate \>10 severe

Time frame

3 months

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Syeda Sana Zaman

Lead sponsor

Hayat Abad Medical Complex, Peshawar

Sponsor institution

Source ClinicalTrials.gov

Apply now